Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Shares Issued: 2018-2024

Historic Shares Issued for Allogene Therapeutics (ALLO) over the last 7 years, with Dec 2024 value amounting to $1.5 million.

  • Allogene Therapeutics' Shares Issued fell 62.15% to $257,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 60.95%. This contributed to the annual value of $1.5 million for FY2024, which is 38.50% down from last year.
  • Per Allogene Therapeutics' latest filing, its Shares Issued stood at $1.5 million for FY2024, which was down 38.50% from $2.5 million recorded in FY2023.
  • Allogene Therapeutics' Shares Issued's 5-year high stood at $595.7 million during FY2020, with a 5-year trough of $1.5 million in FY2024.
  • Over the past 3 years, Allogene Therapeutics' median Shares Issued value was $2.5 million (recorded in 2022), while the average stood at $2.2 million.
  • As far as peak fluctuations go, Allogene Therapeutics' Shares Issued spiked by 20,039.62% in 2020, and later slumped by 98.60% in 2021.
  • Yearly analysis of 5 years shows Allogene Therapeutics' Shares Issued stood at $595.7 million in 2020, then slumped by 98.60% to $8.3 million in 2021, then plummeted by 70.51% to $2.5 million in 2022, then increased by 1.42% to $2.5 million in 2023, then plummeted by 38.50% to $1.5 million in 2024.